The lethal interaction between ERBB1/2/4 inhibitors and ruxolitinib was not only discovered in mammary tumor cells but was also found in HCT116 colon, A498 renal and MiaPaca2 pancreatic and multiple NSCLC cells, including the July 2015 ERBB3-dependent ADOR isolate (Figure 1C). Here, ERBB3 is linked to non-small cell lung carcinoma.